Impact of Daridorexant, a Dual Orexin Receptor Antagonist, on Cardiac Repolarization Following Bedtime Dosing: Results from a Thorough QT Study Using Concentration-QT Analysis

Authors: Schilling U, Henrich A, Muehlan C, Krause A, Dingemanse J, Ufer M
Publication: Clinical Drug Investigation
Keywords: cardiac repolarization, concentration-QT analysis, daridorexant, insomnia

Abstract

Background and Objective: Daridorexant is a new dual orexin receptor antagonist currently in late-stage clinical development for the treatment of insomnia. This randomized, double-blind, placebo-controlled, four-period crossover study investigated the effect of daridorexant at a therapeutic and supratherapeutic dose on QT interval duration.

By Uta Schilling, Andrea Henrich, Clemens Muehlan, Andreas Krause, Jasper Dingemanse, Mike Ufer